SEC Form SC 13G filed

2/8/21 10:17:35 AM ET

Biotechnology: Laboratory Analytical Instruments

Industrials

Get the next $BIO alert in real time by email

SC 13G 1 filing.txt SCHEDULE 13G Amendment No. 0 BIO-RAD LABORATORIES INC CLASS A COMMON STOCK Cusip #090572207 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #090572207 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 270,714 Item 6: 0 Item 7: 1,692,254 Item 8: 0 Item 9: 1,692,254 Item 11: 6.840% Item 12: HC Cusip #090572207 Item 1: Reporting Person - Abigail P. Johnson Item 2: (a) [ ] (b) [ ] Item 4: United States of America Item 5: 0 Item 6: 0 Item 7: 1,692,254 Item 8: 0 Item 9: 1,692,254 Item 11: 6.840% Item 12: IN Item 1(a). Name of Issuer: BIO-RAD LABORATORIES INC Item 1(b). Address of Issuer's Principal Executive Offices: 1000 Alfred Nobel Drive Hercules, CA 94547 Item 2(a). Name of Person Filing: FMR LLC Item 2(b). Address or Principal Business Office or, if None, Residence: 245 Summer Street, Boston, Massachusetts 02210 Item 2(c). Citizenship: Not applicable Item 2(d). Title of Class of Securities: CLASS A COMMON STOCK Item 2(e). CUSIP Number: 090572207 Item 3. This statement is filed pursuant to Rule 13d-1(b) or 13d-2(b) or (c) and the person filing, FMR LLC, is a parent holding company in accordance with Section 240.13d-1(b)(1)(ii)(G). (Note: See Exhibit A). Item 4. Ownership (a) Amount Beneficially Owned: 1,692,254 (b) Percent of Class: 6.840% (c) Number of shares as to which such person has: (i) sole power to vote or to direct the vote: 270,714 (ii) shared power to vote or to direct the vote: 0 (iii) sole power to dispose or to direct the disposition of: 1,692,254 (iv) shared power to dispose or to direct the disposition of: 0 Item 5. Ownership of Five Percent or Less of a Class. Not applicable. Item 6. Ownership of More than Five Percent on Behalf of Another Person. One or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the CLASS A COMMON STOCK of BIO-RAD LABORATORIES INC. No one other person's interest in the CLASS A COMMON STOCK of BIO-RAD LABORATORIES INC is more than five percent of the total outstanding CLASS A COMMON STOCK. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. See attached Exhibit A. Item 8. Identification and Classification of Members of the Group. Not applicable. Item 9. Notice of Dissolution of Group. Not applicable. Item 10. Certifications. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. Signature After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. February 5, 2021 Date /s/ Kevin M. Meagher Signature Kevin M. Meagher Duly authorized under Power of Attorney effective as of September 28, 2018, by and on behalf of FMR LLC and its direct and indirect subsidiaries* * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on October 9, 2018, accession number: 0000315066-18-002414. Exhibit A Pursuant to the instructions in Item 7 of Schedule 13G, the following table lists the identity and Item 3 classification, if applicable, of each relevant entity that beneficially owns shares of the security class being reported on this Schedule 13G. Entity ITEM 3 Classification FIAM LLC IA Fidelity Institutional Asset Management Trust Company BK Fidelity Management & Research Company LLC * IA FMR Investment Management (UK) Limited FI Strategic Advisers LLC IA * Entity beneficially owns 5% or greater of the outstanding shares of the security class being reported on this Schedule 13G. Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. Neither FMR LLC nor Abigail P. Johnson has the sole power to vote or direct the voting of the shares owned directly by the various investment companies registered under the Investment Company Act ("Fidelity Funds") advised by Fidelity Management & Research Company LLC ("FMR Co. LLC"), a wholly owned subsidiary of FMR LLC, which power resides with the Fidelity Funds' Boards of Trustees. FMR Co. LLC carries out the voting of the shares under written guidelines established by the Fidelity Funds' Boards of Trustees. This filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned, by FMR LLC, certain of its subsidiaries and affiliates, and other companies (collectively, the "FMR Reporters"). This filing does not reflect securities, if any, beneficially owned by certain other companies whose beneficial ownership of securities is disaggregated from that of the FMR Reporters in accordance with Securities and Exchange Commission Release No. 34-39538 (January 12, 1998). RULE 13d-1(k)(1) AGREEMENT The undersigned persons, on February 5, 2021, agree and consent to the joint filing on their behalf of this Schedule 13G in connection with their beneficial ownership of the CLASS A COMMON STOCK of BIO-RAD LABORATORIES INC at December 31, 2020. FMR LLC By /s/ Kevin M. Meagher Kevin M. Meagher Duly authorized under Power of Attorney effective as of September 28, 2018, by and on behalf of FMR LLC and its direct and indirect subsidiaries* Abigail P. Johnson By /s/ Kevin M. Meagher Kevin M. Meagher Duly authorized under Power of Attorney effective as of September 30, 2018, by and on behalf of Abigail P. Johnson* * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on October 9, 2018, accession number: 0000315066-18-002414.

Get the next $BIO alert in real time by email

Recent Analyst Ratings for

$BIO

Date	Price Target	Rating	Analyst
10/1/2024	$350.00 → $400.00	Neutral → Buy	Citigroup
8/28/2024	$340.00	Equal Weight	Wells Fargo
6/3/2024	$315.00	Hold	Jefferies
4/3/2024	$400.00 → $365.00	Buy → Neutral	Citigroup
12/7/2023	$395.00	Buy	UBS
6/16/2023	$550.00	Overweight	Wells Fargo
12/7/2022	$565.00	Outperform	RBC Capital Mkts
8/25/2022	$715.00	Outperform	Credit Suisse

More analyst ratings

SEC Form SC 13G filed

Chat with this insight

Recent Analyst Ratings for
$BIO

$BIO
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 3: New insider May Simon claimed ownership of 43 units of Bio-Rad A Common Stock

SEC Form 4: Wright Dara converted options into 502 units of Bio-Rad A Common Stock and covered exercise/tax liability with 221 units of Bio-Rad A Common Stock, increasing direct ownership by 46% to 892 units

SEC Form 4: Schwartz Norman D received a gift of 40 units of Bio-Rad B Common Stock, increasing direct ownership by 0.01% to 316,146 units

$BIO
Financials

Live finance-specific insights

Bio-Rad Reports First-Quarter 2025 Financial Results

Bio-Rad to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025

Bio-Rad Reports Fourth-Quarter and Full-Year 2024 Financial Results

$BIO
SEC Filings

Bio-Rad Laboratories, Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

SEC Form 10-Q filed by Bio-Rad Laboratories, Inc.

Bio-Rad Laboratories, Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

$BIO
Press Releases

Fastest customizable press release news feed in the world

Bio-Rad Reports First-Quarter 2025 Financial Results

Biodesix partner, Friends of Cancer Research, publishes data in Clinical Cancer Research, demonstrating strong association between ctDNA changes and treatment outcomes for patients with solid tumor types

Bio-Rad to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025

$BIO
Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13G/A filed